http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2008247947-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b754d0a365e53d5e5abfc23599ea2a4e |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K51-083 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K51-088 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K51-08 |
| filingDate | 2007-04-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1de81452f0c503c0cf37c57b6fd688e9 |
| publicationDate | 2008-10-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-2008247947-A1 |
| titleOfInvention | High dose 111In-pentetreotide therapy of neuroendocrine tumors |
| abstract | A method for treating a neuroendocrine tumor is disclosed, which includes administering a first dose of 111 In-pentetreotide to a subject having the neuroendocrine tumor; and administering a second dose of 111 In-pentetreotide to the subject after a selected duration has elapsed after the administering of the first dose, wherein the first dose and the second dose are each about 400 mCi or higher, and wherein the selected duration is at least a week. In another method, the first dose and the second dose are each about 500 mCi and the selected duration is between 10 and 12 weeks. The method may further include administration of a third dose. A composition for treating a neuroendocrine tumor includes 111 In-pentetreotide having a radioactivity of about 400 mCi or higher in a single dose. |
| priorityDate | 2007-04-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 109.